Pipeline Update at BioLineRx - Analyst Blog


Pipeline updates are highly awaited events for investors in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These companies spend a significant amount in advancing their pipelines.

One such biopharma company is BioLineRx ( BLRX ) whose pipeline includes candidates like BL-8040 (acute myeloid leukemia (AML) and other hematological cancer indications, currently in a phase II study), BL-5010 (non-surgical removal of skin lesions, a pivotal CE-mark registration trial to start in the first half of 2014), BL-1040 (preventing pathological cardiac remodelling following a myocardial infarction, currently in a pivotal CE-Mark registration trial) and BL-7010 (for celiac disease, currently in a phase I/II study).

Recently, BioLineRx announced the successful completion of the single administration, dose-escalation stage of the ongoing phase I/II study on BL-7010. BL-7010 is being evaluated for the treatment of celiac disease. The results showed positive safety and tolerability levels. There were no dose-limiting safety issues and serious adverse events found.

The repeated administration stage of the study will soon be initiated. In this stage of the study, patients will receive either BL-7010 or placebo thrice per day for a period of two weeks. Results from the phase I/II study will be out in mid-2014. Assuming successful completion of this study, BioLineRx expects to conduct a randomized, controlled, efficacy study at the end of this year, in patients suffering from celiac disease. 

In the ongoing double-blind, placebo-controlled, dose escalation, two-part study, the primary endpoint is the evaluation of the safety of single and repeated ascending doses of BL-7010 in well-controlled celiac patients. The secondary endpoint is the assessment of systemic exposure of BL-7010 in these patients.

We note that BL-7010 is developed by BioLineRx under a worldwide exclusive license agreement with Univalor.

BioLineRx carries a Zacks Rank #2 (Buy). Investors looking for better-ranked stocks in the biopharma sector may consider companies like Questcor Pharmaceuticals, Inc. ( QCOR ), Shire ( SHPG ) and Alkermes ( ALKS ), all of which carry a Zacks Rank #1 (Strong Buy).

ALKERMES INC (ALKS): Free Stock Analysis Report

BIOLINE RX LTD (BLRX): Get Free Report

QUESTCOR PHARMA (QCOR): Free Stock Analysis Report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: ALKS , BLRX , QCOR , SHPG



More from Zacks.com:

Related Videos



Most Active by Volume

  • $17.88 ▼ 1.38%
  • $18.51 ▼ 6.98%
  • $94.01 ▼ 1.26%
  • $121.30 ▼ 0.87%
  • $23.28 ▼ 9.17%
  • $14.20 ▼ 0.77%
  • $14.83 ▼ 1.79%
  • $46.70 ▼ 0.38%
As of 7/31/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com